Next Article in Journal
Influence of Materials Properties on Bio-Physical Features and Effectiveness of 3D-Scaffolds for Periodontal Regeneration
Next Article in Special Issue
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
Previous Article in Journal
Dialkylboryl-Substituted Cyclic Disilenes Synthesized by Desilylation-Borylation of Trimethylsilyl-Substituted Disilenes
Previous Article in Special Issue
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma

The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer

Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy
Centro Ricerche Medicina Sperimentale, Azienda Ospedaliera Universitaria, Città della Salute e della Scienza di Torino, 10126 Turin, Italy
Computer Science Department, University of Turin, 10126 Turin, Italy
Author to whom correspondence should be addressed.
Academic Editors: Amedeo Amedei and Elena Niccolai
Molecules 2021, 26(6), 1642;
Received: 29 January 2021 / Revised: 2 March 2021 / Accepted: 11 March 2021 / Published: 15 March 2021
(This article belongs to the Special Issue The Future of the Cancer Treatment: The Immunotherapy Next Generation)
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of human cancer, characterized by unrestrained progression, invasiveness and treatment resistance. To date, there are limited curative options, with surgical resection as the only effective strategy, hence the urgent need to discover novel therapies. A platform of onco-immunology targets is represented by molecules that play a role in the reprogrammed cellular metabolism as one hallmark of cancer. Due to the hypoxic tumor microenvironment (TME), PDA cells display an altered glucose metabolism—resulting in its increased uptake—and a higher glycolytic rate, which leads to lactate accumulation and them acting as fuel for cancer cells. The consequent acidification of the TME results in immunosuppression, which impairs the antitumor immunity. This review analyzes the genetic background and the emerging glycolytic enzymes that are involved in tumor progression, development and metastasis, and how this represents feasible therapeutic targets to counteract PDA. In particular, as the overexpressed or mutated glycolytic enzymes stimulate both humoral and cellular immune responses, we will discuss their possible exploitation as immunological targets in anti-PDA therapeutic strategies. View Full-Text
Keywords: pancreatic cancer; glycolysis; immunotherapies pancreatic cancer; glycolysis; immunotherapies
Show Figures

Graphical abstract

MDPI and ACS Style

Curcio, C.; Brugiapaglia, S.; Bulfamante, S.; Follia, L.; Cappello, P.; Novelli, F. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Molecules 2021, 26, 1642.

AMA Style

Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Molecules. 2021; 26(6):1642.

Chicago/Turabian Style

Curcio, Claudia, Silvia Brugiapaglia, Sara Bulfamante, Laura Follia, Paola Cappello, and Francesco Novelli. 2021. "The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer" Molecules 26, no. 6: 1642.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop